The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Jones Cecilia since 2022.
This trader's CIK number is 1840056.
At the time of last reporting, Jones Cecilia was the Chief Financial Officer of Agios Pharmaceuticals, Inc.. (stock ticker symbol AGIO).
Also see all insider trading activities at Agios Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | AGIO | 0 | $0 | 1,780 | $59,701 | 6,000 | $0 |
| 2024 | AGIO | 0 | $0 | 4,428 | $165,447 | 12,853 | $0 |
| 2023 | AGIO | 0 | $0 | 3,776 | $99,307 | 12,852 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2022 | LOGC | 0 | $0 | 0 | $0 | 5,939 | $0 |
1. Agios Pharmaceuticals, Inc. (AGIO)
2. Logicbio Therapeutics, Inc. (LOGC)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-06-24 | AGIO | Option Ex | 6,000 | .00 | 0 |
| 2025-06-24 | AGIO | Sale | 1,780 | 33.54 | 59,701 |
| 2024-09-26 | AGIO | Sale | 2,542 | 49.03 | 124,634 |
| 2024-09-26 | AGIO | Option Ex | 7,473 | .00 | 0 |
| 2024-01-20 | AGIO | Option Ex | 5,380 | .00 | 0 |
| 2024-01-24 | AGIO | Sale | 1,886 | 21.64 | 40,813 |
| 2023-09-26 | AGIO | Option Ex | 7,472 | .00 | 0 |
| 2023-09-28 | AGIO | Sale | 2,179 | 24.79 | 54,017 |
| 2023-06-28 | AGIO | Option Ex | 5,380 | .00 | 0 |
| 2023-06-30 | AGIO | Sale | 1,597 | 28.36 | 45,290 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-01-11 | LOGC | Option Ex | 5,939 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Jones Cecilia (Chief Financial Officer of Agios Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.